or Try an Advanced Search...

    Technical Analysis for ZVSA - ZyVersa Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 3.61 -3.93% -0.15
    ZVSA closed down 3.93 percent on Monday, July 1, 2024, on 12 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical ZVSA trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Down Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Outside Day Range Expansion -3.93%
    Wide Bands Range Expansion -3.93%
    Oversold Stochastic Weakness -3.93%
    Stochastic Buy Signal Bullish -0.21%
    NR7 Range Contraction -0.21%
    Older End-of-Day Signals for ZVSA ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 7 hours ago
    Down 3% about 7 hours ago
    Fell Below Previous Day's Low about 7 hours ago
    Down 2 % about 7 hours ago
    Down 1% about 7 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    ZVSA Chart by TradingView
    Basic chart:

    Profile

    • Earnings date: Unknown
    ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop product candidates that address high unmet medical needs in the areas of renal and inflammatory diseases. ZyVersa's development pipeline includes phase 2a ready VAR 200, a cholesterol efflux mediator for treatment of rare kidney disease, focal segmental glomerulosclerosis. ZyVersa believes VAR 200 has potential to treat other glomerular diseases, including Alport syndrome and diabetic kidney disease. ZyVersa's development pipeline also includes IC 100, a novel inflammasome ASC inhibitor being developed to treat a multitude of inflammatory diseases.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Organ Systems Kidney Disease Inflammatory Diseases Kidney Diabetic Nephropathy Alport Syndrome Diabetic Kidney Disease Focal Segmental Glomerulosclerosis Glomerulosclerosis Inflammasome Stage Specialty Biopharmaceutical

    Is ZVSA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 21 Peering Into ZyVersa Therapeutics's Recent Short Interest
    May 15 ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
    May 14 ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
    Apr 29 Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Apr 29 What's Going On With ZyVersa Stock?
    Apr 26 Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Apr 4 ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
    Mar 25 ZyVersa Therapeutics GAAP EPS of -$0.29
    Mar 25 ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
    Mar 18 ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease
    See more ZVSA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 115.15
    52 Week Low 3.4101
    Average Volume 255,110
    200-Day Moving Average 15.69
    50-Day Moving Average 4.88
    20-Day Moving Average 4.44
    10-Day Moving Average 4.12
    Average True Range 0.42
    RSI (14) 35.90
    ADX 23.95
    +DI 12.93
    -DI 27.28
    Chandelier Exit (Long, 3 ATRs) 4.08
    Chandelier Exit (Short, 3 ATRs) 4.68
    Upper Bollinger Bands 5.58
    Lower Bollinger Band 3.31
    Percent B (%b) 0.13
    BandWidth 51.12
    MACD Line -0.36
    MACD Signal Line -0.28
    MACD Histogram -0.0828
    Fundamentals Value
    Market Cap 5.94 Million
    Num Shares 1.64 Million
    EPS -78.43
    Price-to-Earnings (P/E) Ratio -0.05
    Price-to-Sales 0.00
    Price-to-Book 0.05
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.84
    Resistance 3 (R3) 3.83 3.74 3.81
    Resistance 2 (R2) 3.74 3.68 3.75 3.79
    Resistance 1 (R1) 3.68 3.64 3.63 3.69 3.78
    Pivot Point 3.59 3.59 3.56 3.59 3.59
    Support 1 (S1) 3.52 3.53 3.48 3.53 3.44
    Support 2 (S2) 3.43 3.49 3.44 3.43
    Support 3 (S3) 3.37 3.43 3.42
    Support 4 (S4) 3.38